Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CGAS | Q8N884 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | STAT3 | P40763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24925369 | 0.93 | KDM4E (0.33) | KDM4EALDH1A1GAAHPGDSTAT3 | |
| SCHEMBL28340678 | 0.79 | EGFR (0.39) | KDM4EALDH1A1GAAHPGDSTAT3 | |
| SCHEMBL25065503 | 0.77 | KDM4E (0.40) | KDM4EALDH1A1GAAHPGDSTAT3 | |
| SCHEMBL25065501 | 0.73 | — | — | |
| SCHEMBL25064821 | 0.72 | — | — | |
| SCHEMBL24868665 | 0.72 | LMNA (0.39) | HPGD | |
| SCHEMBL17885790 | 0.72 | ALDH1A1 (0.47) | KDM4EALDH1A1GAAHPGDSTAT3 | |
| SCHEMBL25092244 | 0.72 | ESR1 (0.36) | KDM4EALDH1A1GAAHPGD | |
| SCHEMBL24875920 | 0.72 | RXFP1 (0.30) | — | |
| SCHEMBL23510469 | 0.71 | TYMS (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048890-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048890-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | CGAS 1720/4885KDM4E 2544/4885ALDH1A1 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.